The classification of PIVKA-II response was based on a prior study (33) involving 235 patients with HCC receiving PD-1 blockade therapy, which demonstrated that a >50% reduction in PIVKA-II levels was significantly associated with prolonged PFS (p=0.021) and OS (p=0.006). Here, PDCD1 is linked to hepatocellular carcinoma.